Earlier this year, Boehringer Ingelheim and Lilly collaborated in the field of diabetes that centers on four pipeline compounds representing several of the largest treatment classes. Tradjenta, which
As per the two-year agreement, the companies will use technology developed at the Massachusetts Eye and Ear Infirmary in the Eaton-Peabody Laboratory by investigator and Audion co-founder Albert
The tie up allows Nycomed to become the sole marketing authorization holder in all the licensed territories. Bonviva is a bisphosphonate used in the treatment of osteoporosis in
The company’s technology suite consists of Enlighten, iMedNet EDC and EMPOWER. Enlighten is a clinical trial management solution contains easy-to-use electronic data capture (EDC) capabilities, data management tools
NeurogesX has recruited around 183 patients for this trial. The Phase 2 clinical study design included two stages. The first stage was intended to establish the shortest tolerable
The new patent entitled, ‘KAPPA-OPIATE AGONISTS FOR THE TREATMENT OF DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME,’ covers the usage of asimadoline in treating diarrhea predominant irritable bowel syndrome (D-IBS). The
Earlier in May 2009, Takeda signed an agreement with Novartis, under which the Switzerland-based Novartis has provided license rights to market and distribute Hib vaccine TAK-816 (Vaxem Hib)
ALKS 5461 is the combination of ALKS 33 and buprenorphine. The trial will evaluate the safety, efficacy and pharmacokinetics of ALKS 5461 in 32 patients who are suffering
All the patients received injections in the lumbar region of the spine only. The trial plans to enroll up to 18 ALS patients, who are both non-ambulatory and
The inspection was done in connection with the Brazilian Ministry of Health’s investigation of the new drug application (NDA) filed with ANVISA for taliglucerase alfa to treat gaucher
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.